DEAR EDITOR, A recently published report by Florek et al. 1 associates malignancies with
ustekinumab (Stelara â) treatment. Janssen emphasizes patient safety and welcomes …

Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …

Dear Editor: Erythrodermic psoriasis is a severe form of psoriasis, presenting as prominent
erythema rather than thick scales, affecting the entirebody including the face, trunk …

Sir, we describe the successful but unlicensed use of ustekinumab to treat severe psoriasis
in a 13-year old girl. Our patient was first seen aged 9 with a 9-month history of severe scalp …

Dear Editor, Psoriasis is an immune-mediated, genetic skin disease affecting 1–2% of the
world's population. Chronic plaque psoriasis accounts for 80–90% of all cases and can …

DEAR EDITOR, Biological drugs are increasingly being prescribed to treat moderate-to-
severe psoriasis. This cohort includes a significant proportion of women of childbearing …

DEAR EDITOR, With the widespread use of monoclonal antibodies directed against
cytokines in the treatment of psoriasis, we are presented with opportunities to investigate …

DEAR EDITOR, Clinical trials of biologics in psoriasis usually evaluate fixed-dosing
regimens. However, patients may need to interrupt therapy for reasons such as surgery …

Background Patients with psoriasis who are treated with systemic and biologic therapies
may have an increased risk of infections, including hepatitis B virus (HBV). Cytokines that …

DEAR EDITOR, Ustekinumab is a human interleukin-12/interleukin-23 monoclonal antibody
that has been approved by the US Food and Drug Administration (FDA) to treat moderate …